Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (September 2025)
23 slides from Island Pharmaceuticals's investor presentation, Sep 17, 2025
Slide 1: Investor presentation: Galidesivir survival rates in Marburg and Ebola animal studies
17 September 2025 ASX Announcement Investor presentation: Galidesivir underpins high level survival rates in Marburg and Ebola animal studies • Galidesivir responsible for 94% overall survival rate in Marburg-infected primates compared to 0% survival in placebo group • 100% survival rate in Ebola-in
Slide 2: Exceptional survival rates in Ebola
Exceptional survival rates in Ebola: BioCryst have also undertaken two non-human primate studies to test Galidesivir’s utility in Ebola. During the initial study, Galidesivir was administered immediately post- infection which led to a 100% survival rate. A follow up study was then undertaken, during
Slide 3: Q&A
trial sites and partners are progressing well and we look forward to providing additional updates in the coming weeks.” Q&A: What differentiates Galidesivir’s efficacy profile in Marburg and Ebola from other antivirals in development? Galidesivir has delivered consistent, high survival rates in stri
Slide 4: Q&A continued: Animal Rule, PRV and timelines
under FDA-agreed protocols, after which the data can be integrated into an NDA submission. Alignment on the use of the Animal Rule for Galidesivir approval in Marburg will discussed at the Company’s proposed meeting with the FDA next quarter. How realistic is the potential to secure a Priority Revie
Slide 5: Contacts and About Island Pharmaceuticals
Approved for release to the ASX by: David Foster (CEO and Managing Director) Island Pharmaceuticals Limited info@islandpharmaceuticals.com Investors and media, for further information, please contact: Henry Jordan Six Degrees Investor Relations +61 (0) 431 271 538 henry.jordan@sdir.com.au About Isla
Slide 6: Combatting Urgent Viral Disease Threats
For personal use only COMBATTING URGENT VIRAL DISEASE THREATS Dr David Foster, CEO & Managing Director September 2025 ASX: ILA
Slide 7: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Island Pharmaceuticals). Not an offer or financial product advice The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and
Slide 8: Island Pharmaceuticals is an antiviral therapeutics company
Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics For personal use only company targeting infectious diseases Engagement underway with US FDA to fast Two, well advanced clinical stage programs track regulatory approval of Galidesivir Major market potential via both programs Positive res
Slide 9: Corporate Overview
CORPORATE OVERVIEW Share on issue¹: 253,776,761 Substantial shareholders Price per share¹: $0.295 Dr William James Garner³ 16.86% Market capitalisation¹: $74.9m Jason Alan Carroll⁴ 12.25% For personal use only Cash at bank (30 June 2025)²: $7.25m MWP Partners Limited⁵ 8.25% Debt Nil Dr Daniel Tillet
Slide 10: Company Overview
COMPANY OVERVIEW • Two clinical stage assets – Galidesivir and ISLA-101 - both with Priority Review Voucher potential based on approval For personal use only • Galidesivir: • Small molecule with broad antiviral activity against numerous high-priority threats • Robust development history with over US
Slide 11: Galidesivir Program Update: Asset overview
GALIDESIVIR PROGRAM UPDATE Asset overview: Multiple opportunities presented across large markets For personal use only 1 2 3 Demonstrated activity Activity against potential Potential markets: against 20+ viruses – bioterror threats ⚬ Government stockpile programs many with no available ⚬ Numerous a
Slide 12: Broad Spectrum Activity Demonstrated
BROAD SPECTRUM ACTIVITY DEMONSTRATED Data highlights activity in vitro against multiple RNA viruses from diverse families Virus Family Virus Strain/Variant Virus Family Virus Strain/Variant For personal use only Marburg Musoke Nipah virus Malaysia Paramyxo HRS A2 Marburg Ci67 Filoviridae Measles Chi
Slide 13: Demonstrated In Vivo Antiviral Effects
DEMONSTRATED IN VIVO ANTIVIRAL EFFECTS Impact achieved with delayed dosing across a broad range of viruses For personal use only Animal Species Virus Dose Regimen Key Results 100% survival initial dose 3dpi, 80% survival initial dose Hamsters Yellow Fever 100 mg/kg BID 7 days 4dpiᵃ; 12.5% survival c
Slide 14: High Efficacy in Marburg Non-Human Primate Study
HIGH EFFICACY IN MARBURG NON-HUMAN PRIMATE STUDY Treated non-human primates showed an overall survival rate of 94% during trial For personal use only Island Pharmaceuticals Limited 09
Slide 15: Marburg Non-Human Primate Study Summary
MARBURG NON-HUMAN PRIMATE STUDY SUMMARY For personal use only Study Group Virus Survivors (number) Total subjects Survival rate (%) Placebo Marburg 0 6 0% Galidesivir (1 hour) Marburg 5 6 83.33% Galidesivir (24 hour) Marburg 6 6 100% Galidesivir (48 hour) Marburg 6 6 100% Island Pharmaceuticals Limi
Slide 16: Promising Efficacy in Ebola via Non-Human Primate Study
PROMISING EFFICACY IN EBOLA VIA NON-HUMAN PRIMATE STUDY Treated non-human primates had an overall survival rate of 78% For personal use only Island Pharmaceuticals Limited 11
Slide 17: Ebola Non-Human Primate Study Summary
EBOLA NON-HUMAN PRIMATE STUDY SUMMARY For personal use only Study Group Virus Survivors (number) Total subjects Survival rate (%) Placebo Ebola 0 6 0% Galidesivir (48 hour) loading dose followed by Ebola 6 6 100% maintenance dose Galidesivir (48 hour) only Ebola 4 6 67% maintenance dose Galidesivir
Slide 18: Potential Regulatory Path
POTENTIAL REGULATORY PATH 4~8 YEARS 4~6 YEARS 1 YEAR In vivo Basic Drug Experiment experiments Phase 1 Phase 2 Phase 3 NDA For personal use only study design in vitro (animal clinical trials clinical trials clinical trials studies) In vivo Basic Drug Experiment experiments Phase 1 Animal Rule NDA st
Slide 19: Galidesivir is designed to protect the backbone of national resilience
GALIDESIVIR IS DESIGNED TO PROTECT THE BACKBONE OF NATIONAL RESILIENCE ILA’s stockpile strategy ensures full treatment coverage for the 10,000+ individuals critical to outbreak containment and continuity of government – from POTUS + Cabinet to Essential Infrastructure Leaders. For personal use only
Slide 20: Animal Rule is a proven path for bioterror threat countermeasures
ANIMAL RULE IS A PROVEN PATH FOR BIOTERROR THREAT COUNTERMEASURES Since 2012, the FDA’s Animal Rule approval has led to 8 bioterror countermeasures joining the US Strategic National Stockpile For personal use only In 7 out of 8 cases, these medical countermeasures continue to remain under SNS contra
Slide 21: Galidesivir transaction
Galidesivir transaction POTENTIAL REGULATORY FAST Due diligence with BioCryst Pharmaceuticals, TRACK Inc. (Nasdaq: BCRX) completed and asset purchase agreement executed Existing Galidesivir data package and FDA Animal Rule unlock quicker approval path Maiden animal study Aim to complete within 12 mo
Slide 22: Near Term Milestones
NEAR TERM MILESTONES A number of value catalysts pending over the coming months for Galidesivir Galidesivir specific milestones Timeframe For personal use only Completion of Galidesivir transaction Complete Submission of documents and meeting request to FDA regarding Galidesivir Q3 CY2025 Sign resea
Slide 23: Island Pharmaceuticals
For personal use only Island Pharmaceuticals ASX: ILA dfoster@islandpharmaceuticals.com islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals
Island Pharmaceuticals — Investor Presentation (September 2025) on 6ix